Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Kitasato Symposium 2011: Translational prospects for cytokines in 2011

Open Badges Oral presentation

Adipocytokines and autoimmunity

Klaus W Frommer, Elena Neumann and Ulf Müller-Ladner*

Author Affiliations

Department of Internal Medicine and Rheumatology, Justus-Liebig University Gießen, Kerckhoff-Klinik, Bad Nauheim, D-61231, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13(Suppl 2):O8  doi:10.1186/ar3412

The electronic version of this article is the complete one and can be found online at:

Published:16 September 2011

© 2011 Frommer et al.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

By definition, adipo(cyto)kines are cytokine-like mediators produced mainly by adipose tissue. In the human body, they participate in regulating a variety of physiological functions related to energy metabolism [1] and inflammation [2]. Increased or decreased adipokine levels are associated with autoimmune diseases including diabetes mellitus type 1 (DMT1) [3], rheumatoid arthritis (RA) [4,5], ankylosing spondylitis (AS) [6], systemic sclerosis (SSc) [7], systemic lupus erythematosus (SLE) [8] and Behçet's disease [9-12].

In vitro data suggest that adipokines may contribute to the progression of RA as they are potent inducers of proinflammatory cytokines, chemokines and matrix metalloproteinases (MMP) in RA effector cells [13-16].

SSc also appears to be associated with adipokines. Contrary to RA, in which substantial intraarticular degradation of extracellular matrix occurs, SSc is characterized by excessive fibrosis. In vitro data and data from animal models of fibrosis point towards a dual role of the adipokine adiponectin as presented by numerous groups at the EULAR congress in London, specifically an antifibrotic effect in later stages of SSc and a profibrotic effect in earlier stages, which appears to be induced by proinflammatory cytokines. Likewise, leptin is involved in the development of liver fibrosis [17-19].

So far, no or only little functional information is available regarding the role of adipokines in other autoimmune diseases. Serum level and clinical correlation analyses, however, suggest an association with adipokines.

In AS, elevated resistin serum levels have been found, while adiponectin levels remained unchanged [6,20]. On the other hand, leptin is discussed controversially in AS. Serum levels were decreased in AS according to two studies [20,21], while they were increased according to another [22]. Also, while correlations of leptin with parameters of inflammation (C-reactive protein, IL-6) and disease activity (Bath Ankylosing Spondylitis Disease Activity Index) have been found by Park et al. [22], no such correlations could be found by Toussirout et al. [20]. Interestingly, peripheral blood mononuclear cells (PBMC) from AS patients express and secrete more leptin, IL-6 and TNF-α than PBMC from control subjects. Additionally, stimulation of PBMC from AS patients with exogenous leptin led to a significantly increased IL-6 and TNF-α production [23]. Hence, leptin might be involved in the pathogenesis of AS.

In SLE, resistin, for example, has been shown to be associated with general inflammation and bone loss, suggesting a proinflammatory and disease-promoting function [24].

However, the exact role of adipokines especially in SSc, AS and SLE is still unclear and will require further investigation. Also, further research is warranted to show whether adipokines may represent potential therapeutic targets in this diseases.


  1. Rajala MW, Scherer PE: Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis.

    Endocrinology 2003, 144:3765-3773. PubMed Abstract | Publisher Full Text OpenURL

  2. Neumann E, Frommer KW, Vasile M, Muller-Ladner U: Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?

    Arthritis Rheum 2011, 63:1159-1169. PubMed Abstract | Publisher Full Text OpenURL

  3. Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W: Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study.

    Eur J Endocrinol 2007, 157:481-489. PubMed Abstract | Publisher Full Text OpenURL

  4. Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J, Müller-Ladner U, Gay S: Adipocytokines in synovial fluid.

    JAMA 2003, 290:1709-1710. PubMed Abstract | Publisher Full Text OpenURL

  5. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jorgensen A, Tarp U, Hetland ML, Horslev-Petersen K, Hornung N, Poulsen JH, et al.: Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.

    J Rheumatol 2009, 36:1885-1891. PubMed Abstract | Publisher Full Text OpenURL

  6. Kocabas H, Kocabas V, Buyukbas S, Melikoglu MA, Sezer I, Butun B: The serum levels of resistin in ankylosing spondylitis patients: a pilot study.

    Rheumatol Int 2010.



  7. Kotulska A, Kucharz EJ, Brzezinska-Wcislo L, Wadas U: A decreased serum leptin level in patients with systemic sclerosis.

    Clin Rheumatol 2001, 20:300-302. PubMed Abstract | Publisher Full Text OpenURL

  8. Harle P, Pongratz G, Weidler C, Buttner R, Scholmerich J, Straub RH: Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis.

    Ann Rheum Dis 2004, 63:809-816. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  9. Ozgen M, Koca SS, Dagli N, Balin M, Ustundag B, Isik A: Serum adiponectin and vaspin levels in rheumatoid arthritis.

    Arch Med Res 2010, 41:457-463. PubMed Abstract | Publisher Full Text OpenURL

  10. Sezen H, Okumus S, Pehlivan Y, Dilli I, Tarakcioglu M, Onat AM: Visfatin Levels in Behcet's Disease.

    Inflammation 2011.



  11. Yalcindag FN, Yalcindag A, Batioglu F, Caglayan O, Kisa U, Ozdemir O: Evaluation of serum resistin levels in patients with ocular and non-ocular Behcet's disease.

    Can J Ophthalmol 2008, 43:473-475. PubMed Abstract | Publisher Full Text OpenURL

  12. Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bulbul M, Ozerol E, Er H, Ozbek E: Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity.

    Br J Dermatol 2002, 147:331-336. PubMed Abstract | Publisher Full Text OpenURL

  13. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Scholmerich J, et al.: The potential of adiponectin in driving arthritis.

    J Immunol 2006, 176:4468-4478. PubMed Abstract | Publisher Full Text OpenURL

  14. Frommer KW, Zimmermann B, Meier FM, Schroder D, Heil M, Schäffler A, Büchler C, Steinmeyer J, Brentano F, Gay S, et al.: Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis.

    Arthritis Rheum 2010, 62:2886-2899. PubMed Abstract | Publisher Full Text OpenURL

  15. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties.

    J Immunol 2005, 174:5789-5795. PubMed Abstract | Publisher Full Text OpenURL

  16. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.

    Arthritis Rheum 2007, 56:2829-2839. PubMed Abstract | Publisher Full Text OpenURL

  17. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N: Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

    Gastroenterology 2002, 122:1399-1410. PubMed Abstract | Publisher Full Text OpenURL

  18. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice.

    Hepatology 2002, 35:762-771. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  19. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J: Kupffer cells mediate leptin-induced liver fibrosis.

    Gastroenterology 2009, 137:713-723. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  20. Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huede G, Saas P, Wendling D: Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis.

    Metabolism 2007, 56:1383-1389. PubMed Abstract | Publisher Full Text OpenURL

  21. Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M, Onen F, Akkoc N: Body composition, insulin, and leptin levels in patients with ankylosing spondylitis.

    Clin Rheumatol 2007, 26:1427-1432. PubMed Abstract | Publisher Full Text OpenURL

  22. Park MC, Lee SW, Choi ST, Park YB, Lee SK: Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis.

    Scand J Rheumatol 2007, 36:101-106. PubMed Abstract | Publisher Full Text OpenURL

  23. Park MC, Chung SJ, Park YB, Lee SK: Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis.

    Joint Bone Spine 2009, 76:170-175. PubMed Abstract | Publisher Full Text OpenURL

  24. Almehed K, d'Elia HF, Bokarewa M, Carlsten H: Role of resistin as a marker of inflammation in systemic lupus erythematosus.

    Arthritis Res Ther 2008, 10:R15. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL